We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu
Trial record 1 of 15 for:    novan
Previous Study | Return to List | Next Study

SB208 for the Treatment of Tinea Pedis

This study is ongoing, but not recruiting participants.
ClinicalTrials.gov Identifier:
First Posted: August 9, 2016
Last Update Posted: January 4, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novan, Inc.
This is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in approximately 170 non immunocompromised adult subjects with interdigital tinea pedis. Subjects will apply the investigational product (IP) (SB208 or Vehicle Gel) to the interdigital areas and all affected and immediate surrounding areas of one or both feet once daily for 2 weeks, followed by a 4-week post-treatment observation period.

Condition Intervention Phase
Tinea Pedis Drug: SB208 2% Drug: SB208 4% Drug: SB208 16% Drug: Vehicle Gel Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Dose-Ranging Study Assessing Efficacy and Safety of SB208 and Vehicle Gel in Subjects With Interdigital Tinea Pedis

Resource links provided by NLM:

Further study details as provided by Novan, Inc.:

Primary Outcome Measures:
  • Fungal culture result [ Time Frame: 2 weeks ]
    Negative fungal culture from target lesion

Secondary Outcome Measures:
  • Clinical cure [ Time Frame: 6 wks ]
    Amelioration of signs and symptoms of tinea pedis

  • Mycological cure [ Time Frame: 6 wks ]
    No evidence of fungal infection based on skin scraping and culture

Other Outcome Measures:
  • Incidence of treatment-emergent adverse events [ Time Frame: 6 weeks ]
    Summary of treatment emergent adverse events by treatment group

Enrollment: 222
Study Start Date: July 2016
Estimated Study Completion Date: June 2017
Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SB208 2% Drug: SB208 2%
SB208 2% once daily
Experimental: SB208 4% Drug: SB208 4%
SB208 4% once daily
Experimental: SB208 16% Drug: SB208 16%
SB208 16% once daily
Placebo Comparator: Vehicle Gel Drug: Vehicle Gel
Vehicle Gel once daily


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Otherwise healthy male and female subjects with clinical diagnosis of interdigital t. pedis
  • T.pedis provisionally confirmed at baseline by a positive KOH wet mount for segmented fungal hyphae on skin scraping from the target site

Exclusion Criteria:

  • Women who are pregnant or nursing or planning on becoming pregnant
  • Subjects with onychomycosis or moccasin-type t. pedis
  • Subjects using topical or systemic anti-fungal agents
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02860052

Dominican Republic
Instituto Dermatológico y Cirugía de Piel,
Santo Domingo, Dominican Republic
Sponsors and Collaborators
Novan, Inc.
Study Director: M Joyce Rico, MD Novan, Inc.
  More Information

Responsible Party: Novan, Inc.
ClinicalTrials.gov Identifier: NCT02860052     History of Changes
Other Study ID Numbers: NI-AF201
First Submitted: August 2, 2016
First Posted: August 9, 2016
Last Update Posted: January 4, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Tinea Pedis
Skin Diseases, Infectious
Skin Diseases
Foot Dermatoses
Foot Diseases
Skin Manifestations
Signs and Symptoms